Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study☆
Section snippets
Background
Streptococcus pneumoniae is the most common bacterial cause of pneumonia, meningitis and sinusitis in adults. Invasive pneumococcal disease (IPD) is a cause of high morbidity and mortality in the elderly as well as in younger adults with particular high-risk comorbidities [1]. Following 7-valent pneumococcal conjugate vaccine (PCV7) introduction in the USA in 2000, a dramatic decrease in IPD incidence was observed. This decrease in IPD in non-vaccinated adult population was attributed to the
Ethics statement
The study was conducted following protocols approved by the Sheba Medical Center Institutional Review Board (IRB) and the Soroka University Medical Center IRB. Since this was a retrospective observational study, the institutional review board waived the need for written informed consent from the participants and informed consent was not obtained. Therefore, all patient records/information were de-identified prior to analysis.
Study period
From July 1, 2009, when PCV7 was introduced to the pediatric NIP for
Vaccine uptake
In 2007–2008, when PCV7 was approved in Israel, but not yet included in the NIP, the proportion of 12–23 month old Jewish children with ≥2 PCV doses was estimated at ∼25%. Bedouin children only rarely received PCVs obtained in any non-NIP frame. In June 2009, 2010, 2011, 2012 and 2013, the proportion of 7–11 month old children who had received ≥2 doses of any PCV was 18%, 81%, 90%, 89% and 89%, respectively. The respective figures for PCV13 were 1%, 3%, 30%, 86% and 89%.
Overall and age-specific IPD incidence
The overall IPD
Discussion
This study reports a full nationwide data, with probably only minimal under-reporting, due to the capture-recapture study design. Only a few other countries have similar good population-based surveillance systems [12], [13], [14]. While IPD notification is mandatory in many European countries, they have reported a wide variation in notification, partly due to different surveillance methods which probably lead to significant under-diagnoses and under-reporting [15]. Moreover, most studies on IPD
Acknowledgments
We greatly acknowledge Ronit Trefler for serotyping, Etti Kreiff and Efrat Steinberger for their assistance in data management. We thank Aviva Goral for assistance in statistical analysis and data management.
The IAIPD is part of the IsraNIP project.
The study was supported in part by Wyeth (Pfizer), manufacturer of Prevnar7 and Prevnar13, grant no. 0887X1-4603. The commercial company had no role in designing the study, collecting the data, data analyses, interpretation of the data, writing the
References (23)
- et al.
Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children
Vaccine
(2012) - et al.
Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis
Respiratory medicine
(2014) - et al.
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
Vaccine
(2014) - et al.
A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7
Vaccine
(2013) - et al.
Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the national immunization plan in Israel
Vaccine
(2012) - et al.
Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme
Vaccine
(2010) - et al.
Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study
Vaccine
(2014) - et al.
European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era
Vaccine
(2014) - et al.
Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance
Vaccine
(2014) - et al.
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
Vaccine
(2011)
Impact of conjugate pneumococcal vaccines on antibiotic resistance
Lancet Infect Dis
Cited by (54)
Constrained Optimization for Pneumococcal Vaccination in Brazil
2021, Value in Health Regional IssuesHospital-onset adult invasive pneumococcal disease in Israel: Sicker patients, different pathogens
2019, International Journal of Infectious DiseasesVaccines to Prevent Pneumococcal Community-Acquired Pneumonia
2018, Clinics in Chest MedicineThe choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes
2018, VaccineCitation Excerpt :For example, in Israel, no data from adults were collected prior to PCV7 introduction. Therefore, studies that assess PCV herd effects in adults in Israel use IRs in the single year of PCV7 introduction as a proxy for baseline incidence [18,41]. Baseline data may also be difficult to obtain for many low-to-middle income countries with weak IPD surveillance systems.
- ☆
Results of this study have been partially presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), at Hyderabad, India, March 2014.